How Migraines Differ from Ordinary Headaches in Biology and Treatment

One Billion People Live with Migraine — and Most Are Misdiagnosed

Migraine ranks as the third most prevalent illness on Earth, affecting roughly 1 billion people worldwide according to the Migraine Research Foundation. Yet surveys consistently show that fewer than half of migraine sufferers receive a correct diagnosis on their first medical visit. The confusion stems from a fundamental misconception: that a migraine is simply a very bad headache. It is not. Migraine is a complex neurological disorder with a distinct biological mechanism, a recognizable sequence of phases, and treatment targets that have nothing to do with ordinary analgesics.

The Biology Behind the Throbbing: Cortical Spreading Depression

The signature pain of a migraine — unilateral, pulsating, aggravated by movement — originates in the brain, not in the skull. The leading mechanistic model centers on cortical spreading depression (CSD), a slow wave of neuronal depolarization that rolls across the cortex at roughly 3–5 mm per minute. This electrical storm silences neurons in its wake and triggers the release of inflammatory molecules that activate the trigeminal nerve, the primary pain pathway for the head and face.

Once the trigeminal nerve fires, it releases calcitonin gene-related peptide (CGRP), a potent vasodilatory neuropeptide. CGRP dilates meningeal blood vessels and amplifies pain signals. This is why CGRP inhibitors — a class of drugs developed in the 2010s — have become a breakthrough in migraine prevention.

Phases of a Migraine Attack

• Prodrome (hours to days before): Mood shifts, food cravings, neck stiffness, and yawning signal hypothalamic activation.
• Aura (20–60 minutes): Visual zigzags, blind spots, or tingling limbs trace the CSD wave as it spreads across sensory cortex. Present in about 25–30% of migraineurs.
• Headache (4–72 hours): Throbbing, typically one-sided pain, often with nausea, vomiting, and extreme sensitivity to light and sound.
• Postdrome: Brain fog, fatigue, and cognitive slowing can persist for 24 hours after pain resolves.

Tension Headaches: A Different Mechanism Entirely

Tension-type headaches (TTH) — the dull, band-like pressure most people experience — arise from sustained contraction of pericranial muscles and peripheral sensitization of myofascial trigger points. There is no CSD. No CGRP surge. No trigeminal cascade. The pain is bilateral, non-pulsating, and mild to moderate in intensity. Ordinary activity does not worsen it, and nausea is rare.

Diagnosis: International Headache Society Criteria

The International Headache Society (IHS) publishes the ICHD-3 classification, the global standard for headache diagnosis. Migraine without aura requires at least five attacks meeting specific criteria: 4–72 hours untreated, two of four pain characteristics, and at least one associated symptom. No biomarker or imaging test can diagnose migraine — it remains a clinical diagnosis based on patient history.

The POUND mnemonic helps clinicians screen: Pulsatile quality, One-day duration (4–72 hours), Unilateral location, Nausea/vomiting, Disabling intensity. Four or five of five features carry a positive likelihood ratio of 24 for migraine.

Why Common Painkillers Often Fail — or Backfire

Over-the-counter analgesics (ibuprofen, acetaminophen) address pain signals at the peripheral level. They don't touch the trigeminal-CGRP cascade driving migraine. Worse, using them more than 10–15 days per month can trigger medication overuse headache (MOH), also called rebound headache, where the brain's pain threshold permanently lowers — creating a vicious cycle of more frequent, harder-to-treat attacks.

Migraine-Specific Treatments

• Triptans: Serotonin 5-HT_1B/1D agonists that constrict dilated cranial vessels and block trigeminal CGRP release. Most effective when taken early in the attack.
• CGRP monoclonal antibodies (preventive): Erenumab, fremanezumab, galcanezumab — monthly or quarterly injections that block CGRP or its receptor, reducing attack frequency by 50% or more in clinical trials.
• Gepants: Small-molecule CGRP receptor antagonists (ubrogepant, rimegepant) effective for both acute and preventive use, safe for patients with cardiovascular contraindications to triptans.
• Ditans: Lasmiditan targets 5-HT_1F receptors without vascular constriction — an option for patients with heart disease.

Triggers, Hormones, and Genetic Risk

Migraine has a strong genetic component. First-degree relatives of migraineurs have a threefold increased risk. Familial hemiplegic migraine is caused by mutations in ion channel genes (CACNA1A, ATP1A2), demonstrating the channelopathy framework for the broader condition.

Triggers lower the threshold for CSD rather than directly causing attacks. Common triggers include hormonal fluctuations (estrogen withdrawal before menstruation is the most consistent), sleep disruption, skipped meals, dehydration, and certain foods. Women experience migraines three times more frequently than men, largely due to estrogen's modulatory effect on trigeminal sensitivity — though the gender gap narrows significantly after menopause.

Chronic Migraine and the Treatment Gap

When attacks occur on 15 or more days per month, with at least eight meeting migraine criteria, the diagnosis shifts to chronic migraine. This affects approximately 2% of the global population and is highly disabling. The World Health Organization classes a severe migraine attack as equivalent in disability to quadriplegia for its duration. Despite this burden, studies indicate that fewer than 13% of chronic migraine patients receive preventive therapy.

This article is for informational purposes only. Consult a qualified healthcare professional for diagnosis and treatment of migraines or any headache disorder.